Abstract:

Nosocomial infection is common in the neonatal intensive care unit. The rapid development of perinatal medicine and medical technology in neonatal intensive care unit has improved the survival of premature infants. With the longer duration of hospitalization, premature infants are exposed to the threat of nosocomial infection. Empiric antimicrobial therapy has resulted in an increase in the proportion of antibiotic-resistant organisms. Multi-resistance is mainly found in Gram-positive bacteria, and Vancomycin is the main treatment. However, the number of Vancomycin-resistant bacteria is increasing, and the potential threat has been a concern. Gram-negative bacteria, including carbapenem-resistant strains, is much more ominous, and the treatment options are extremely limited. Non-first-line drugs such as Colistin and Tigecycline are more frequently used, while intensive management should be done in application of these drugs on neonates for severe infection.

Key words: antibiotic-resistant organisms, neonates, advances in management